Please provide your email address to receive an email when new articles are posted on . Cannabidiol treatment was associated with median reduction of 67% to 99% in focal aware seizures. All ...

CHICAGO — Azetukalner (AZK), a novel and potent Kv7 potassium channel opener, reduced median seizure frequency by up to 53% in patients with treatment-resistant focal onset seizures (FOS) in a phase 3 ...

Please provide your email address to receive an email when new articles are posted on . Seizure freedom was observed by 12 months and continued past 48 months of the open-label extension. Long-term ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. A positive readout of a Rapport ...

Los Angeles — Only about 27% of patients newly diagnosed with focal epilepsy are seizure-free on initial anti-seizure medications (ASMs), new research suggested. This is sobering information to pass ...

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures The CORE-VNS 36-month data analysis reaffirms the effectiveness of VNS Therapy ...

More than 3.4 million people in the United States have epilepsy, so it is a relatively common diagnosis. In fact, it is the fourth-most common neurologic condition in the world. November is National ...

Seizures can affect your daily life and well-being. Certain medicines can help lower the risk of having seizures, which can help manage your condition. Fycompa is a medicine used to manage ...

Focal-onset seizures (FOSs) are the most common type of seizure experienced by epileptic individuals. A recent randomized control trial published in JAMA Neurology evaluated the effect of a novel ...

Robust efficacy, competitive tolerability and ease of administration. Those are the qualities for a potential blockbuster antiseizure medication, according to Abe Ceesay, CEO of Rapport Therapeutics ...